Estrogen and neuroprotection: higher constitutive expression of glutaredoxin in female mice offers protection against MPTP-mediated neurodegeneration.
Incidence of Parkinson's disease is lower in women as compared with men. Although neuroprotective effect of estrogen is recognized, the underlying molecular mechanisms are unclear. MPTP (1-methyl-4-phenyl-1, 2, 3, 6, tetrahydro-pyridine), a neurotoxin that causes Parkinson's disease-like symptoms acts through inhibition of mitochondrial complex I. Administration of MPTP to male mice results in loss of dopaminergic neurons in substantia nigra, whereas female mice are unaffected. Oxidation of critical thiol groups by MPTP disrupts mitochondrial complex I, and up-regulation of glutaredoxin (a thiol disulfide oxidoreductase) is essential for recovery of complex I. Early events following MPTP exposure, such as increased AP1 transcription, loss of glutathione, and up-regulation of glutaredoxin mRNA is seen only in male mice, indicating that early response to neurotoxic insult does not occur in females. Pretreatment of female mice with ICI 182,780, estrogen receptor (ER) antagonist sensitizes them to MPTP-mediated complex I dysfunction. Constitutive expression of glutaredoxin is significantly higher in female mice as compared with males. ICI 182,780 down-regulates glutaredoxin activity in female mouse brain regions (midbrain and striatum), indicating that glutaredoxin expression is regulated through estrogen receptor signaling. Higher constitutive expression of glutaredoxin could potentially contribute to the neuroprotection seen in female mouse following exposure to neurotoxins, such as MPTP.
Kenchappa
Rajappa S
RS
Division of Molecular and Cellular Neuroscience, National Brain Research Centre, Nainwal Mode, Manesar, India.
Diwakar
Latha
L
Annepu
Jayasree
J
Ravindranath
Vijayalakshmi
V
D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology; D000818:Animals; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004298:Dopamine / Q000378:metabolism; D042967:Electron Transport Complex I / Q000378:metabolism; D004958:Estradiol / Q000031:analogs & derivatives* / Q000494:pharmacology; D004965:Estrogen Antagonists / Q000494:pharmacology; D004967:Estrogens / Q000502:physiology*; D005260:Female; D000077267:Fulvestrant; D054477:Glutaredoxins; D005978:Glutathione / Q000378:metabolism; D008297:Male; D008636:Mesencephalon / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008928:Mitochondria / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000032:analysis; D009498:Neurotoxins / Q000633:toxicity; D010088:Oxidoreductases / Q000096:biosynthesis / Q000235:genetics / Q000502:physiology*; D020734:Parkinsonian Disorders / Q000209:etiology; D011960:Receptors, Estrogen / Q000378:metabolism; D012727:Sex Characteristics; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis; D014451:Ubiquinone / Q000494:pharmacology
D004965:Estrogen Antagonists; D004967:Estrogens; D054477:Glutaredoxins; D009419:Nerve Tissue Proteins; D009498:Neurotoxins; D011960:Receptors, Estrogen; D014451:Ubiquinone; D000077267:Fulvestrant; D004958:Estradiol; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D010088:Oxidoreductases; D014446:Tyrosine 3-Monooxygenase; D042967:Electron Transport Complex I; D005978:Glutathione; D004298:Dopamine